No Increased Risk of Cardiovascular Events with Dutasteride vs Finasteride

    December 2016 in “ Reactions Weekly
    Image of study
    TLDR Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.
    A 10-year study conducted in Canada found that dutasteride, a 5-alpha reductase inhibitor used to treat benign prostatic hyperplasia (BPH), is not associated with an increased risk of cardiovascular (CV) events compared to finasteride, another 5-alpha reductase inhibitor. The study involved male residents of Ontario, Canada, aged 26-66 years who were newly treated with either dutasteride or finasteride. The primary analysis revealed no difference in the risk of hospitalization for heart failure in patients treated with dutasteride versus finasteride. The researchers concluded that their results should provide reassurance to physicians and patients of the equivalent safety of dutasteride and finasteride for BPH.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 1 year ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  40 upvotes 5 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 7 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    1 / 1 results